Sun Zhaoyang, Liu Yiran, Chen Anwei, Wang Tao, Liu Shaohua
Department of Oral and Maxillofacial Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Department of Oral and Maxillofacial Surgery, Weifang People's Hospital, Weifang, Shandong, China.
Front Neurol. 2024 Aug 16;15:1444896. doi: 10.3389/fneur.2024.1444896. eCollection 2024.
Foam sclerotherapy is currently the first-line treatment for venous malformations (VMs). Hyaluronic acid-polidocanol (HA-POL) foam has been used in the treatment of head and neck VMs recently; however, its clinical efficacy and safety have yet to be further evaluated, and the impact of age and other related factors on its safety is still unclear.
To assess the efficacy and safety of HA-POL foam in the treatment of head and neck VMs.
We performed a single-center retrospective review of all patients with VMs involving the head and neck region undergoing HA-POL foam sclerotherapy from February 2015 to February 2022 in the Oral and Maxillofacial Surgery Department of Qilu Hospital Shandong University. Patients' medical records were collected and all patients enrolled were followed up for 1-6 months (group 1), part of them were followed up for 3-9 years (group 2).
A total of 223 patients with head and neck VMs were enrolled in the study, with 36 patients who were followed for 3-9 years. Total response rate in group 1 was 96.41% ( = 215), of which 30.94% ( = 69) of the patients met the criteria of "resolution," and 65.47% ( = 146) of the patients had "significant improvement." In group 2, the total response rate was 72.22% ( = 26), of which the rates of the patients met the criteria of "resolution" and patients had "significant improvement" were all 36.11% ( = 13)0.144 (64.57%) patients experienced complications like localized swelling, pain and fever, and no serious complications occurred. The risk of developing complications after treatment was independent of age, and was weakly associated with the dose of HA-POL foam.
The HA-POL foam sclerotherapy is safe and effective in the treatment of head and neck VMs.
泡沫硬化疗法目前是静脉畸形（VMs）的一线治疗方法。透明质酸-聚多卡醇（HA-POL）泡沫最近已用于头颈部VMs的治疗；然而，其临床疗效和安全性尚有待进一步评估，年龄及其他相关因素对其安全性的影响仍不明确。
评估HA-POL泡沫治疗头颈部VMs的疗效和安全性。
我们对2015年2月至2022年2月在山东大学齐鲁医院口腔颌面外科接受HA-POL泡沫硬化疗法治疗的所有头颈部VMs患者进行了单中心回顾性研究。收集患者的病历资料，所有纳入研究的患者随访1-6个月（第1组），部分患者随访3-9年（第2组）。
本研究共纳入223名头颈部VMs患者，其中36例随访3-9年。第1组的总有效率为96.41%（n=215），其中30.94%（n=69）的患者达到“消退”标准，65.47%（n=146）的患者“显著改善”。第2组的总有效率为72.22%（n=26），其中达到“消退”标准和“显著改善”的患者比例均为36.11%（n=13）。0.144（64.57%）的患者出现局部肿胀、疼痛和发热等并发症，未发生严重并发症。治疗后发生并发症的风险与年龄无关，与HA-POL泡沫的剂量弱相关。
HA-POL泡沫硬化疗法治疗头颈部VMs安全有效。
